Helix BioPharma Raises C$3.67M in Convertible Debenture Offering

VANCOUVER, BC - Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCF, FRANKFURT: HBP0), a clinical-stage oncology company, has announced the closing of a non-brokered private placement of unsecured convertible debentures, raising C$3,673,000. The company issued 3,673 Convertible Debentures with a 14-month maturity and a 25% simple interest rate. If not repaid by maturity, holders may convert principal into common shares at C$1.42 per share (market price less 20% discount), and accrued interest into shares at the higher of the conversion price or the volume-weighted average trading price over five days. Proceeds will fund general working capital and advance drug development programs, including Tumor Defense Breaker™ L-DOS47, a clinical-stage antibody-enzyme conjugate for CEACAM6-expressing tumors, and preclinical candidates LEUMUNA™ (oral immune checkpoint modulator) and GEMCEDA™ (oral gemcitabine prodrug). Helix's shares trade on TSX, OTC PINK, and Frankfurt. The debentures and underlying shares are subject to a four-month hold period.

Helix BioPharma is focused on making hard-to-treat cancers vincible. Their pipeline includes L-DOS47, which completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares a CEACAM6-targeting foundation with next-generation bi-specific ADCs. LEUMUNA™ aims for durable remission in post-transplant leukemia relapse, while GEMCEDA™ offers an oral gemcitabine with IV-level bioavailability. The company's leadership, including CEO Thomas Mehrling, MD, PhD, emphasizes innovation from strength to bring near-term solutions. This financing provides capital to progress these promising therapies toward clinical milestones.

The original release was distributed via NEWMEDIAWIRE and is available at www.newmediawire.com. Forward-looking statements involve risks detailed in the company's filings on SEDAR+.